Pembrolizumab in combination with pemetrexed and cisplatin is in clinical development for the
treatment of adult patients with advanced malignant pleural mesothelioma (MPM). MPM is a rare
variation of cancer that affects the internal chest wall and the outer linings of the lungs.
Mesothelioma is often diagnosed at an advanced stage and surgery is not always possible.
Treatment is usually given to manage the symptoms such as fatigue and shortness of breath caused
by MPM, although patients tend to respond poorly to current chemotherapy and radiation therapy.
Pembrolizumab in combination with pemetrexed and cisplatin for previously untreated advanced malignant pleural mesothelioma
Pembrolizumab in combination with pemetrexed and cisplatin is in clinical development for the treatment of adult patients with advanced malignant pleural mesothelioma (MPM). MPM is a rare variation of cancer that affects the internal chest wall and the outer linings of the lungs.
Interventions:
Cisplatin (Platinol)
, Pembrolizumab (Keytruda; MK-3475)
, Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)
Indications:
Malignant pleural mesothelioma (MPM)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2021